Dr. Daniel B. Apple, M.D.
Ophthalmology (Ophthalmology Physician)
- Medicare participating
At a glance
- Medical school
- University of South Carolina School of Medicine (2011)
- Years since graduation
- 15
- In the NPI registry since
- 2011
- Medicare patients seen, 2024
- 945
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2011Medical school: University of South Carolina School of Medicine
- 2011Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Ophthalmology Physician primary
MI license 4301109284
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Prisma Health Greenville Memorial Hospital Greenville, SC
- Spartanburg Medical Center Spartanburg, SC
- St Francis-Downtown Greenville, SC
Medical groups
- Retina Consultants of Carolina, PA (11 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 945
- Services billed
- 30,408
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Injection, faricimab-svoa, 0.1 mg | 13,320 | 43 |
| Imaging of retina | 2,338 | 941 |
| Injection, aflibercept, 1 mg | 1,442 | 161 |
| Injection of drug into eye | 1,160 | 268 |
| Established patient office or other outpatient visit, 20-29 minutes | 1,125 | 371 |
| Established patient complete exam of visual system | 917 | 665 |
| Injection, ranibizumab, 0.1 mg | 352 | 22 |
| Injection, bevacizumab, 10 mg | 258 | 76 |
| New patient office or other outpatient visit, 45-59 minutes | 206 | 206 |
| Injection, dexamethasone, intravitreal implant, 0.1 mg | 161 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisolone Acetate Other prescribers in Detroit, MI | 134 |
| Ketorolac Tromethamine Other prescribers in Detroit, MI | 75 |
| Ofloxacin Other prescribers in Detroit, MI | 57 |
| Brimonidine Tartrate Other prescribers in Detroit, MI | 41 |
| Atropine Sulfate | 12 |
| Erythromycin (erythromycin base) Other prescribers in Detroit, MI | 12 |
| Prolensa (bromfenac sodium) | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 19 payments worth $502 in total to this clinician.
| Bausch & Lomb Americas Inc. | $143 |
|---|---|
| Genentech USA, Inc. | $127 |
| AbbVie Inc. | $66.26 |
| Ani Pharmaceuticals, Inc. | $59.49 |
| Astellas Pharma US Inc | $50.74 |
| Apellis Pharmaceuticals, Inc. | $36.64 |
| Regeneron Healthcare Solutions, Inc. | $19.62 |
| Food and Beverage | $502 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $14,205 in research payments for these studies, mostly to the institutions running them.
- A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
Regeneron Pharmaceuticals, Inc. · Recruiting · NCT06541704
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.